Reuters logo
BRIEF-Genmab announces preliminary cervical cancer data from tisotumab vedotin phase I/II study
June 16, 2017 / 5:45 PM / 3 months ago

BRIEF-Genmab announces preliminary cervical cancer data from tisotumab vedotin phase I/II study

June 16 (Reuters) - Genmab A/S

* Genmab announces preliminary cervical cancer data from tisotumab vedotin phase i/ii study

* Genmab says considering plans for further clinical development of tisotumab vedotin in cervical cancer

* Genmab - conjunctivitis was identified as a tisotumab vedotin specific toxicity, which led to introducing of prophylactic management

* Genmab - in cervical cancer cohort, 15 patients experienced one or more grade 3 adverse events

* Genmab - safety profile of tisotumab vedotin consistent with known mmae based antibody-drug conjugates including peripheral neuropathy and neutropenia Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below